The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

Respiratory Research

Table 4 Taste-related adverse events (conventional analysis)

	Filapixant (N = 23)				Placebo (N = 23)
Adverse event	20 mg	80 mg	150 mg	250 mg	(20 mg)	(80 mg)	(150 mg)	(250 mg)
(MedDRA preferred term)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Ageusia	0	1 (4.3%)	1 (4.3%)	0	0	0	0	0
Dysgeusia	1 (4.3%)	0	3 (13.0%)	5 (21.7%)	0	0	2 (8.7%)	0
Hypogeusia	0	1 (4.3%)	1 (4.3%)	1 (4.3%)	0	0	0	0
Taste disorder NOS	0	1 (4.3%)	4 (17.4%)	1 (4.3%)	1 (4.3%)	0	0	0
Total number of patients reporting such events	1 (4.3%)	2 (8.7%)	8 (34.8%)	6 (26.1%)	1 (4.3%)	0	2 (8.7%)	0

Percentages refer to the total number of patients (N = 23)
This table shows data only for the dose level at which the event first occurred, regardless of whether the event continued or recurred at subsequent dose levels. Adverse events were coded using MedDRA v22.0

ISSN: 1465-993X